{"filings":[{"id":889476,"accession_number":"0001628280-26-041298","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2026-06-05T20:38:13+00:00","items":["5.07"],"status":"ready","headline":"Vanda shareholders re-elect three Class II directors and approve equity plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Dugan, Duncan, and Ward re-elected with majority support; broker non-votes of ~10M shares.","Shareholders ratified PwC as auditor for FY 2026 with 48.1M votes for.","Advisory say-on-pay passed; ~35.2M for, ~3.2M against.","Amendment to 2016 Equity Plan to increase authorized shares approved with 31.7M for, 6.7M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92359,"accession_number":"0001628280-26-031241","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vanda Q1 net loss widens to $0.82/share; raises FY2026 revenue guidance on NEREUS launch","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Fanapt net product sales $29.6M (+26% YoY); total prescriptions +32%, new-to-brand +76%.","NEREUS (tradipitant) launched via direct-to-consumer platform; first new motion sickness drug in 40+ years.","FY2026 revenue guidance raised to $240-290M from $230-260M, including $10-30M from NEREUS.","Net loss $48.6M ($0.82 diluted EPS) vs loss $29.5M ($0.50) in Q1 2025.","BYSANTI (milsaperidone) received FDA approval Feb 20 for bipolar I and schizophrenia."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":51718000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92358,"accession_number":"0001628280-26-026642","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Vanda Pharmaceuticals appoints Dr. Charles Duncan to Board of Directors effective April 22, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expands from six to seven members; Duncan appointed as Class II director with term ending at 2026 annual meeting.","Initial RSU award of $390,000 vests quarterly over four years; annual cash retainer of $50,000.","Additional annual RSU award of $260,000 after each annual meeting starting 2026, vesting one year later.","Duncan previously Managing Director at Cantor Fitzgerald, covering >70 biotech companies; founded Sulci Advisors in Sep 2025.","Duncan cites recent approvals of NEREUS and BYSANTI, label expansion for Fanapt, and pipeline catalysts over next 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92357,"accession_number":"0001628280-26-023222","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vanda Pharmaceuticals General Counsel Timothy Williams resigns, effective Apr 10, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy Williams resigns as SVP, General Counsel and Secretary, effective April 10, 2026.","No successor or interim replacement announced; search process not disclosed.","Resignation is to pursue other endeavors; no conflict or disagreement noted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103161,"accession_number":"0001628280-26-016516","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Vanda CEO reveals NEREUS launch plan: DTC channel, availability in months","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["NEREUS approved by FDA for prevention of vomiting induced by motion sickness.","CEO disclosed development of direct-to-consumer channel NEREUSRX for NEREUS access.","NEREUS will be available in the next couple of months per CEO on Fox Business.","Pricing and commercial strategy for NEREUS discussed during interview."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103160,"accession_number":"0001628280-26-010376","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vanda Pharmaceuticals receives FDA approval for Bysanti (milsaperidone) for bipolar I disorder and schizophrenia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Bysanti (milsaperidone) approved for acute manic/mixed episodes of bipolar I disorder and schizophrenia in adults.","Bysanti is a new chemical entity that interconverts to iloperidone, leveraging 100,000+ patient-years of real-world experience.","Vanda expects commercial availability in Q3 2026; marketing exclusivity protected by patents expiring in 2044.","This is Vanda's second new drug approval in less than 2 months, following NEREUS in December 2025.","Bysanti is being tested as a once-daily adjunctive for treatment-resistant major depressive disorder, study completion expected by end of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103159,"accession_number":"0001628280-26-009805","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Vanda Pharmaceuticals sets 2025 bonuses, 2026 salaries, and grants RSUs/PSUs to executives","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Polymeropoulos gets $834,326 2025 bonus; 2026 base $994,625, target bonus 80%.","Other NEOs 2025 bonuses $272k-$282k; 2026 base $576,735-$596,990, target 45%.","RSUs: 525,000 to CEO, 125,000 to each of four other NEOs; vest in 4 equal annual installments.","PSUs: target 175,000 (CEO), 40,000 (others); payout 0%-150% based on relative TSR vs Nasdaq Biotech Index over 3 years.","Compensation Committee used Willis Towers Watson peer analysis in determining compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103158,"accession_number":"0001628280-26-007256","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vanda FY2025: Fanapt sales +24% to $117.3M; net loss $220.5M; guides 2026 rev $230-260M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Fanapt net product sales $117.3M (+24% YoY); total revenues $216.1M (+9%); total prescriptions +28%, NBRx +149%.","Net loss $220.5M ($3.74 diluted EPS) includes $113.7M non-cash valuation allowance; adjusted net loss $106.8M ($1.81 EPS).","FDA approved NEREUS (tradipitant) for motion-induced vomiting; Bysanti NDA PDUFA Feb 21, 2026; imsidolimab BLA submitted.","FY2026 guidance: total revenue $230-260M (Fanapt $150-170M; other products $80-90M).","Cash & equivalents $263.8M as of Dec 31, 2025, down $110.8M from Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":216105000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103157,"accession_number":"0001628280-26-001273","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA rejects Vanda's HETLIOZ sNDA for jet lag disorder after expedited re-review","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA concluded sNDA cannot be approved in current form, citing phase advance protocols not sufficiently analogous to actual jet travel.","FDA acknowledged positive efficacy from controlled trials but said data do not provide substantial evidence of effectiveness.","Vanda respectfully disagrees and will pursue all appropriate avenues for approval; notes prior D.C. Circuit ruling set aside FDA refusal.","Expedited re-review was completed by Jan 7, 2026 under collaborative framework agreement from October 2025.","HETLIOZ (tasimelteon) currently approved for non-24-hour sleep-wake disorder; jet lag would be new indication."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119399,"accession_number":"0001628280-25-059155","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves Vanda's NEREUS (tradipitant) for motion sickness prevention; first new drug in 40+ years","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved NEREUS (tradipitant) on Dec 30, 2025 for prevention of vomiting induced by motion; first new drug class for motion sickness in >40 years.","Pivotal Phase 3 trials: vomiting incidence 18.3-19.5% with NEREUS vs 44.3% placebo (Motion Syros, p<0.0001); 10.4-18.3% vs 37.7% (Motion Serifos, p≤0.0014).","Vanda plans to launch NEREUS in coming months; also advancing tradipitant for gastroparesis and GLP-1 agonist-induced nausea.","Mechanism: NK-1 receptor antagonist, targets substance P pathway underlying nausea/vomiting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119398,"accession_number":"0001628280-25-055393","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA lifts partial clinical hold on Vanda's tradipitant for motion sickness","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA lifted partial clinical hold on protocol VP-VLY-686-3403, removing the 90-dose cap on tradipitant studies.","Lift followed Vanda's formal dispute resolution and expedited re-review under October 2025 collaborative framework.","FDA agreed motion sickness is acute, event-driven; no additional dog toxicity study required.","NDA for tradipitant to prevent vomiting due to motion remains under review; PDUFA date December 30, 2025.","CEO Mihael Polymeropoulos thanked FDA for swift scientific review and constructive dialogue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119397,"accession_number":"0001628280-25-054225","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA extends parcial clinical hold re-review to Dec 5; PDUFA date remains Dec 30 for tradipitant","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA and Vanda agreed to extend partial clinical hold re-review target to Dec 5, 2025 (from Nov 26) due to CDER personnel transitions.","PDUFA action date for tradipitant NDA for motion sickness vomiting prevention unchanged at December 30, 2025.","FDA issued labeling comments; labeling discussions with Vanda have formally commenced.","Vanda aims to deliver first new pharmacologic treatment for motion sickness in over 40 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119396,"accession_number":"0001628280-25-047112","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vanda Q3 revenue up 18% to $56.3M but net loss widens to $22.6M; guidance lowered","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net product sales $56.3M (+18% YoY): Fanapt $31.2M (+31%), HETLIOZ $18.0M (+1%), PONVORY $7.0M (+20%).","Net loss $22.6M (diluted EPS -$0.38) vs loss $5.3M (-$0.09) in Q3 2024.","FY2025 guidance: revenue $210-$230M (prev. $210-$250M); year-end cash $260-$290M (prev. $280-$320M).","Pipeline: Tradipitant NDA PDUFA Dec 30, 2025; Bysanti NDA Feb 21, 2026; Imsidolimab BLA filing expected Q4 2025.","Cash $293.8M at Sep 30, 2025, down $80.9M from Dec 31, 2024 and $31.8M from Jun 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":158889000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119395,"accession_number":"0001628280-25-043489","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vanda reaches FDA framework to resolve disputes on HETLIOZ and tradipitant","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA expedited re-review of tradipitant clinical hold by Nov 26, 2025; PDUFA date Dec 30, 2025.","FDA expedited re-review of HETLIOZ sNDA for jet lag by Jan 7, 2026; Part 12 proceedings paused.","Vanda dismisses two lawsuits: one on tradipitant clinical hold (M.D. Fla.) and one on HETLIOZ info (S.D. Tex.).","Both parties seek temporary pause of tradipitant gastroparesis administrative proceedings until Jan 7, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135950,"accession_number":"0001628280-25-036843","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vanda Q2 net loss widens to $27.2M; Fanapt sales up 27% to $29.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Fanapt net product sales $29.3M (+27% YoY); HETLIOZ $16.2M (-13%), PONVORY $7.1M (-18%).","Net loss $27.2M (diluted EPS -$0.46) vs. net loss $4.5M (-$0.08) in Q2 2024.","Cash $325.6M, down $15.4M from Q1 2025; full-year revenue guidance reaffirmed $210-250M.","Regulatory milestones: Bysanti NDA PDUFA Feb 21, 2026; Tradipitant NDA PDUFA Dec 30, 2025; Imsidolimab BLA submission expected 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":102631000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152974,"accession_number":"0001628280-25-029678","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vanda shareholders elect directors, ratify auditor, approve say-on-pay and equity plan amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 46,577,816 shares (79.0%) represented at June 5, 2025 annual meeting.","Directors Stephen Ray Mitchell and Tage Honoré elected with ~31.5M and ~31.3M votes for, respectively.","Ratification of PricewaterhouseCoopers LLP as auditor for FY2025: 43.8M for, 2.3M against.","Advisory say-on-pay approved: 28.6M for, 10.1M against, 7.7M broker non-votes.","Amendment to 2016 Equity Incentive Plan (increase shares, eliminate term) approved: 33.0M for, 5.7M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152973,"accession_number":"0001628280-25-023154","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vanda Q1 net loss widens to $29.5M; Fanapt sales up 14% but PONVORY down 18%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $50.0M (+5% YoY); net loss $29.5M vs $4.1M loss a year ago.","Diluted EPS -$0.50; loss reflects $15M imsidolimab license fee and higher commercial spend.","Fanapt sales $23.5M (+14%), HETLIOZ $20.9M (+4%), PONVORY $5.6M (-18%).","Cash $340.9M; full-year guidance: revenues $210-250M, year-end cash $280-320M.","Tradipitant NDA PDUFA Dec 30, 2025; Bysanti NDA PDUFA Feb 21, 2026; imsidolimab BLA expected 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":50041000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171761,"accession_number":"0001193125-25-055287","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Vanda announces FDA accepted tradipitant NDA for motion sickness; PDUFA Dec 30, 2025; firm criticizes timeline","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted for filing Vanda's NDA for tradipitant to treat motion sickness; PDUFA target date set for December 30, 2025.","Vanda says FDA intends to take 12 months for review, 6 months beyond the statutory deadline, calling it a violation of the FD&C Act.","Clinical data from pooled studies (681 subjects): vomiting in 14.6% (170 mg) and 18.9% (85 mg) vs 41.2% placebo, p<0.0001.","Vanda publicly criticized the FDA as 'broken and unaccountable' for allegedly stifling innovation and delaying approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171760,"accession_number":"0001193125-25-030780","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vanda Pharma discloses 2024 bonuses, 2025 salaries, and RSU grants for NEOs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Polymeropoulos: 2024 bonus $947,928; 2025 base salary $965,655; target bonus 80%; 450,000 RSUs.","CFO Moran and three SVPs: 2024 bonuses $309,181–$320,040; 2025 base $559,935–$579,600; 45% target; 125,000 RSUs each.","All RSUs vest in four equal annual installments commencing March 1, 2026.","Compensation Committee considered peer-group analysis by Willis Towers Watson before approving."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171759,"accession_number":"0001628280-25-005406","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vanda Q4 2024 revenue $53.2M (+17% YoY); guides 2025 rev $210-250M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss $4.9M vs $2.4M loss in Q4 2023; Fanapt sales $26.6M (+18% YoY).","Full year 2024 revenue $198.8M (+3%); net loss $18.9M vs net income $2.5M in 2023.","2025 revenue guidance $210-250M; targets psychiatry portfolio >$750M by 2030.","Bysanti NDA for bipolar/schizophrenia expected Q1 2025; Tradipitant NDA for motion sickness submitted Q4 2024.","Imsidolimab BLA for generalized pustular psoriasis expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":198772000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171758,"accession_number":"0001193125-25-012740","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Vanda files NDA for tradipitant to treat motion sickness","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Vanda disclosed via 8-K that it filed a New Drug Application for tradipitant for motion sickness.","Announcement made via social media post on X on January 25, 2025, referencing WWII context.","No approval or timeline provided; filing is a regulatory step toward potential commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188754,"accession_number":"0001628280-24-045724","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vanda Q3 2024 revenue up 23% to $47.7M; guidance raised; net loss $5.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total net product sales $47.7M (+23% YoY); Fanapt $23.9M (+12%), HETLIOZ $17.9M (+2%), PONVORY $5.9M (-32% QoQ).","Net loss $5.3M vs net income $0.1M in Q3 2023; diluted EPS loss $0.09.","Cash $376.3M; guidance raised: FY revenue $190-210M, year-end cash $370-390M.","Fanapt bipolar I launch: new patient starts +90% Q3 2024 vs Q3 2023; Fanapt LAI Phase III starts Q4 2024.","Milsaperidone NDA for schizophrenia/bipolar I expected early 2025; tradipitant NDA for motion sickness in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":145587000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188753,"accession_number":"0001193125-24-237220","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vanda rejects Cycle Group's $8.00/share acquisition proposal as undervaluing company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Board unanimously determined second unsolicited proposal from Cycle Group not in best interests; terms identical to earlier May bid.","Proposal valued at $8.00/share in cash; Board says it substantially undervalues Vanda.","Board cited clinical pipeline, commercial presence, and cash balance as sources of greater value.","Second Cycle Group proposal received Sept 23, 2024; prior proposal May 24, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188752,"accession_number":"0001193125-24-232306","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Vanda amends bylaws with clarifications on special meetings, advance notice, and director nominations","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Board approved amended bylaws effective October 2, 2024; changes include clarifying special meeting scope to agenda topics only.","Advance notice provisions for shareholder nominations and proposals expanded with additional disclosure requirements.","Adjournment process clarified for meetings relying on remote communication due to technical failure.","Proxy solicitation requirements and director candidate standards spelled out more explicitly.","Special board meetings may now be called by a majority of directors; officer definition narrowed to exclude non-officer title holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205225,"accession_number":"0001193125-24-221784","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA issues Complete Response Letter declining Vanda's tradipitant NDA for gastroparesis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA declined to approve tradipitant for gastroparesis on Sept 18, 2024; issued CRL citing need for additional studies.","FDA action was delayed by over 185 days, Vanda says fails requirements of FDCA.","Vanda believes application met substantial evidence standard and plans to continue pursuing approval.","Separate NDA for tradipitant in prevention of vomiting from motion sickness planned later this year.","Expanded access program continues for several dozen gastroparesis patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205224,"accession_number":"0001193125-24-196481","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"Vanda amends Rights Agreement to clarify definitions of Acting in Concert and Beneficial Owner","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Entered Amendment No. 2 to Rights Agreement on August 7, 2024 with Equiniti Trust Company as rights agent.","Amendment makes punctuation corrections to the definition of 'Acquiring Person'.","Amends and restates definitions of 'Acting in Concert' and 'Beneficial Owner' for clarifying changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205223,"accession_number":"0001628280-24-033743","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vanda Q2 2024 revenue $50.5M (+10% YoY); net loss $4.5M; Fanapt bipolar launch underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 total revenues $50.5M (up 10% YoY); net loss $4.5M vs net income $1.5M in Q2 2023.","Fanapt approved for bipolar I disorder; commercial launch initiated in Q3 2024; PONVORY launch for MS also started.","Tradipitant NDA for gastroparesis under FDA review; PDUFA date Sept 18, 2024; FDA preliminary notice of deficiencies.","HETLIOZ net sales $18.7M (-15% YoY) amid generic competition; lawsuit vs Teva/Apotex allowed to proceed.","Full-year 2024 guidance: total revenues $180-210M; year-end cash $360-390M; cash $387.7M at June 30."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":97936000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222106,"accession_number":"0001193125-24-164545","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vanda Board rejects two unsolicited takeover proposals, citing undervaluation","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cycle Group bid $8.00/share cash; Future Pak offered $8.50-$9.00/share plus CVRs.","Board determined both proposals substantially undervalue Vanda and not in best interests.","Board cites robust revenue, strong cash position, and clinical pipeline as intrinsic value.","No shareholder action required at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222105,"accession_number":"0001193125-24-160755","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vanda confirms revised unsolicited takeover proposal from Future Pak at $8.50-$9.00 per share plus CVRs","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Future Pak LLC proposes $8.50-$9.00 per share cash plus Contingent Value Rights for Vanda Pharmaceuticals.","Vanda Board will review the revised non-binding proposal with financial and legal advisors.","No shareholder action required at this time; company will not comment further until Board completes review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222104,"accession_number":"0001193125-24-156117","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vanda receives unsolicited acquisition proposal from Cycle Group at $8.00/share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cycle Group Holdings Ltd. made an unsolicited, non-binding proposal to acquire Vanda for $8.00 per share in cash.","The proposal is subject to further review; no definitive agreement has been reached.","Vanda's Board will evaluate the indication with independent financial and legal advisors.","No shareholder action is required at this time; the Company will not comment further until Board review is complete.","Cycle Group's offer represents a premium over Vanda's recent closing price (not specified in filing)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222103,"accession_number":"0001628280-24-025254","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vanda Pharmaceuticals Board Rejects Revised Unsolicited Takeover Bid from Future Pak","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Future Pak offered $7.25-$7.75 per share in cash plus Contingent Value Rights to acquire Vanda.","Board unanimously rejected the proposal, stating it substantially undervalues the company and creates significant risk.","Board highlights Vanda's clinical pipeline, expanding commercial presence, and strong cash position as value drivers.","No shareholder action required; board remains confident in long-term value creation exceeding the offer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222096,"accession_number":"0001628280-24-025241","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K/A","filed_at":"2024-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vanda board rejects conditional resignation of director Chrousos after less-than-majority vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Director Phaedra S. Chrousos received less than majority votes at 2024 annual meeting, tendered conditional resignation.","Board (excluding Chrousos) unanimously voted May 22, 2024 to reject resignation, citing qualifications and proxy advisory firm's recommendation related to Rights Agreement.","Chrousos will continue as director until Vanda's 2027 annual meeting or until successor elected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222102,"accession_number":"0001628280-24-024405","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vanda director Chrousos fails re-election, tenders resignation after majority withhold vote","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Phaedra S. Chrousos received 20,071,828 for vs 22,780,322 against; less than majority of votes cast.","Chrousos resigned under company bylaws; Nominating/Governance Committee to decide acceptance.","Directors Polymeropoulos and Chrousos elected; Polymeropoulos got 33,976,239 for, 8,943,623 against.","Stockholders ratified PwC as auditor (44,750,588 for, 1,739,295 against) and approved say-on-pay.","Equity plan amendment passed (34,411,032 for, 8,565,705 against) to increase authorized shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222101,"accession_number":"0001628280-24-021658","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vanda Q1 revenue $47.5M, net loss $4.1M; Fanapt bipolar approval, PONVORY launch in Q3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.1M (diluted EPS -$0.07) vs net income $3.3M ($0.06) in Q1 2023; revenue $47.5M, -24% YoY.","Cash increased $5.9M to $394.1M; Fanapt approved for acute bipolar I disorder, launch Q3 2024.","PONVORY commercial launch in multiple sclerosis expected Q3 2024; tradipitant NDA for gastroparesis under FDA review with PDUFA Sept 18, 2024.","Milsaperidone NDA for schizophrenia and bipolar expected early-2025; tradipitant motion sickness Phase III results Q2 2024.","No FY 2024 guidance given due to HETLIOZ generic competition and upcoming launches."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":47462000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222100,"accession_number":"0001193125-24-133252","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vanda receives revised unsolicited takeover proposal from Future Pak at $7.25-$7.75/share plus CVRs","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Revised proposal of $7.25-$7.75 per share in cash plus Contingent Value Rights (CVRs).","Vanda's Board will evaluate the proposal with its financial and legal advisors.","Prior proposal at same price range was rejected by Vanda.","No shareholder action required at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222099,"accession_number":"0001193125-24-130668","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"Vanda amends Rights Agreement to exempt BlackRock from poison pill up to 20% ownership","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment adds BlackRock and its managed funds as 'Exempt Person' under the Rights Agreement.","BlackRock may acquire up to 20% of Vanda's common stock without triggering the poison pill.","Exempt status can be revoked immediately if BlackRock breaches representations or conditions.","The Board deems the amendment desirable based on BlackRock's representations and warranties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222098,"accession_number":"0001193125-24-099251","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2024-04-17T23:59:59+00:00","items":["1.01","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Vanda adopts limited-duration rights plan; rejects Future Pak's $7.25-$7.75/share bid","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted a one-year stockholder rights plan effective April 17, 2024, triggered at 10% beneficial ownership.","Plan adopted in response to unsolicited proposals from Future Pak; latest offered $7.25–$7.75 per share.","Board unanimously rejected proposals as significantly undervaluing the company, citing robust pipeline and $6.75 cash per share.","Rights dividend payable to shareholders of record April 29, 2024; rights expire April 16, 2025.","Plan prevents open-market accumulation without a control premium; no shareholder action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222097,"accession_number":"0001193125-24-086031","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vanda's Fanapt receives FDA approval for bipolar I disorder indication","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Fanapt (iloperidone) on April 2, 2024 for acute treatment of manic or mixed episodes in bipolar I disorder in adults.","Approval based on pivotal study of ~400 patients; primary endpoint YMRS at Week 4 highly statistically significant (p=0.000008).","Fanapt was previously approved for schizophrenia in 2009; safety profile consistent across indications.","Vanda CEO cites significant increase in commercial opportunity; bipolar I disorder affects ~10M Americans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241628,"accession_number":"0001193125-24-062241","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA issues Complete Response Letter for Vanda's HETLIOZ insomnia sNDA","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received CRL on March 4, 2024 for HETLIOZ (tasimelteon) to treat insomnia with sleep initiation difficulties.","FDA stated deficiencies precluding approval; sNDA cannot be approved in present form.","Vanda reviewing CRL and evaluating next steps; no specific financial impact disclosed.","PDUFA date was March 4, 2024; FDA had flagged deficiencies on February 4, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241627,"accession_number":"0001193125-24-041514","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vanda approves 2023 bonuses, 2024 salaries, and RSU grants for NEOs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Polymeropoulos receives $983K bonus for 2023, 450,000 RSUs vesting over 4 years.","2024 base salaries: CEO $933K, CFO Moran $541K, others $541-560K.","2024 target bonuses: 80% CEO, 45% for other NEOs.","RSU grants total 857,700 shares across five executives.","Compensation committee reviewed Willis Towers Watson peer group analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241624,"accession_number":"0001193125-24-038517","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K/A","filed_at":"2024-02-16T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vanda files financials for PONVORY acquisition; product line had $553.7M loss in FY2023 on $17.8M sales","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price $100M for U.S./Canadian rights of PONVORY (ponesimod) from Johnson & Johnson.","FY2023 net sales $17.8M, up from $3.9M in prior year; direct expenses $571.6M.","Non-cash impairment of $426.1M on intangible asset, reducing net book value to $36.8M.","Direct expenses exceeded sales by $553.7M; prior year excess was $160.3M.","Vanda also filed unaudited pro forma condensed combined financials for year ended Dec 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241626,"accession_number":"0001628280-24-003693","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vanda reports FY2023 revenue $192.6M (-24% YoY); Q4 net loss $2.4M; PDUFA dates in 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2023 net product sales $192.6M, down 24% from $254.4M; Q4 net loss $2.4M vs income $6.9M in Q4 2022.","HETLIOZ sales fell 47% YoY in Q4 due to generic at-risk launches; Fanapt down 7%; PONVORY added $1.6M post-acquisition Dec 7.","Ended 2023 with $388.3M cash, down $78.6M; $100M spent on PONVORY acquisition.","Three PDUFA target action dates in 2024: HETLIOZ insomnia March 4 (FDA cited deficiencies, Vanda sued), Fanapt bipolar April 2, tradipitant gastroparesis Sept 18.","Vanda unable to provide 2024 financial guidance due to HETLIOZ patent litigation and generic competition."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":192640000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241625,"accession_number":"0001193125-24-024112","cik":1347178,"company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA identifies deficiencies in Vanda's sNDA for HETLIOZ insomnia; Vanda alleges FDCA violation","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA notified Vanda on Feb 4, 2024 of deficiencies in sNDA for HETLIOZ (tasimelteon) for insomnia; no details disclosed.","Vanda claims FDA violated FDCA by missing statutory deadline of Oct 31, 2023, to approve or provide a hearing.","sNDA submitted May 4, 2023; PDUFA target date was March 4, 2024; deficiencies preclude labeling discussions.","Vanda is also challenging FDA approvals of generic HETLIOZ, which have been marketed since 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":360210000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}